Disclosures
Richard M. Dubinsky, MD, MPH, FAAN
| Scientific Advisory Boards | |
| Allergan Pharmaceuticals, Scientific Advisory board on the treatment of cervical dystonia and chronic daily headache. Head, | |
| Funding for travel or speaker honoraria | |
| Allergan Pharamceuticals, Irvine, CA, travel and honoraria | |
| Speakers' Bureaus | |
| Allergan Pharmaceuticals | |
| Research Support, Commercial Entities | |
| Allergan Pharmaceuticals Auspex Pharmaceuticals, through a sub-contract through the University of Rochester, Site Investigator ENROLL-HD Longitudinal natural history study of Huntington’s disease. B. Landwehrmeyer, PI, Funded by Cure Huntington’s Disease Initiative. 2015–present. Site Investigator NN105 | |
| Research Support, Government Entities | |
| R01NS052592, R01NS052619-01 (Cudkowicz,M, PI) 07/01/08 – 06/30/14 NIAM and NINDS Coenyzme q10 in Huntington's disease (2-CARE) The goal of this project is to determine if high doses of Co Enzyme Q10 can slow the progression of Huntington’s disease Role: site investigator 2007P000827, UO1AT000613 (Hersch,S, PI) 10/01/08 – 09/30/15 NIH/NCCAM and FDA Orphan Products Division Creatine Safety, Tolerability, & Efficacy in Huntington’s disease (CREST-E), The goal of this project is to determine if high doses of creatine can slow the progression of Huntington’s disease Role: site investigator 1R18 HS22004-01 (Narayanaswami, P., PI) 12/1/2012–11/30/15 HHS/AHRQ/PCORI Dissemination of the Clinical Practice Guideline entitled Complementary and Alternative Medicine in Multiple Sclerosis: Comparison of traditional and new innovative techniques This study compares social media dissemination methods to the standard passive dissemination methods for the to be published in fall 2013 AAN practice parameter on complimentary and alternative medications in the treatment of Multiple sclerosis. Role: Co-investigator CERN Grant DR21-05415 October 2015–July 2016 PRE CELL. PI: Vickie Wheelock. Mesenchymal Stem Cells engineered to produce BDNF in HD. Role: Head of Data Safety Monitoring Board NN105 (STAIR) January 2016 – June 2017 PI: Steven Hersch, MD, PhD NN PI. An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity or a Novel Vasopressin la Receptor Antagonist (SRX246) in Irritable Subjects with Huntington's Disease (IID) Azevan Pharmaceuticals Role: Site investigator | |
| Stock/Stock Options/Board of Directors Compensation | |
| Abbott Labs and Abbvie. Wife owns stock | |